In Vivo Observation of Endothelial Cell-Assisted Vascularization in Pancreatic Cancer Xenograft Engineering

Original Article
  • 60 Downloads

Abstract

In this study, for better understanding of patient-derived xenograft (PDX) generation, angiogenic characteristics during PDX cancerous tissue generation was investigated with different initial cell seeding conditions in the hydrogel. We monitored the angiogenic changes during the formation of in vivo cancer cell line xenografts induced by endothelial cells. Our in vivo cancer tissue formation system was designed with the assistance of tissue engineering technology to mimic patient-derived xenograft formation. Endothelial cells and MIA PaCa-2 pancreatic carcinoma cells were encapsulated in fibrin gel at different mixing configurations and subcutaneously implanted into nude mice. To investigate the effect of the initial cancerous cell distribution in the fibrin gel, MIA PaCa-2 cells were encapsulated as a homogeneous cell distribution or as a cell aggregate, with endothelial cells homogeneously distributed in the fibrin gel. Histological observation of the explanted tissues after different implantation periods revealed three different stages: isolated vascular tubes, leaky blood vessels, and mature cancerous tissue formation. The in vivo engineered cancerous tissues had leaky blood vessels with low expression of the vascular tight junction marker CD31. Under our experimental conditions, complex cancer-like tissue formation was most successful when tumorous cells and endothelial cells were homogeneously mixed in the fibrin gel. The present study implies that tumorous xenograft tissue formation can be achieved with a low number of initial cells and that effective vascularization conditions can be attained with a limited volume of patient-derived cancer tissue. Endothelial cell-assisted vascularization can be a potent choice for the effective development of vascularized cancerous tissues for studying patient-derived xenografts, cancer angiogenesis, cancer metastasis, and anticancer drugs.

Keywords

Cancer tissue engineering Vascularization Patient-derived xenograft Pancreatic cancer 

Notes

Funding

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (Grant Number: NRF-2015K1A4A3046807), by the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Grant Number: HI14C2640) and by the ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Korea (Grant Numbers: 2013-7206, 2014-7201, 2015-7213).

Compliance with ethical standards

Conflict of interest

There are no conflicts to declare.

Ethical statement

The animal experiment protocol was reviewed and approved by the institutional animal care and use committee of Asan Medical Center (Protocol Number: 2014-12-003).

References

  1. 1.
    Bianco P, Robey PG. Stem cells in tissue engineering. Nature. 2001;414:118–21.CrossRefPubMedGoogle Scholar
  2. 2.
    Langer R, Vacanti JP. Tissue engineering. Science. 1993;260:920–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Karam JP, Muscari C, Montero-Menei CN. Combining adult stem cells and polymeric devices for tissue engineering in infarcted myocardium. Biomaterials. 2012;33:5683–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Zhang K, Huang D, Yan Z, Wang C. Heparin/collagen encapsulating nerve growth factor multilayers coated aligned PLLA nanofibrous scaffolds for nerve tissue engineering. J Biomed Mater Res A. 2017;105:1900–10.CrossRefPubMedGoogle Scholar
  5. 5.
    Hoganson DM, Bassett EK, Vacanti JP. Lung tissue engineering. Front Biosci (Landmark Ed). 2014;19:1227-39.CrossRefPubMedGoogle Scholar
  6. 6.
    Bishi DK, Mathapati S, Venugopal JR, Guhathakurta S, Cherian KM, Verma RS, et al. A patient-inspired ex vivo liver tissue engineering approach with autologous mesenchymal stem cells and hepatogenic serum. Adv Healthc Mater. 2016;5:1058–70.CrossRefPubMedGoogle Scholar
  7. 7.
    Szabó DJ, Noer A, Nagymihály R, Josifovska N, Andjelic S, Veréb Z, et al. Long-term cultures of human cornea limbal explants form 3D structures ex vivo—implications for tissue engineering and clinical applications. PLoS One. 2015;10:e0143053.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Pina S, Oliveira JM, Reis RL. Natural-based nanocomposites for bone tissue engineering and regenerative medicine: a review. Adv Mater. 2015;27:1143–69.CrossRefPubMedGoogle Scholar
  9. 9.
    Kashte S, Jaiswal AK, Kadam S. Artificial bone via bone tissue engineering: current scenario and challenges. Tissue Eng Regen Med. 2017;14:1–14.CrossRefGoogle Scholar
  10. 10.
    Kiyuna T, Murakami T, Tome Y, Igarashi K, Kawaguchi K, Russell T, et al. Labeling the stroma of a patient-derived orthotopic xenograft (PDOX) mouse model of undifferentiated pleomorphic soft-tissue sarcoma with red fluorescent protein for rapid non-invasive imaging for drug screening. J Cell Biochem. 2017;118:361–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Fong EL, Martinez M, Yang J, Mikos AG, Navone NM, Harrington DA, et al. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Mol Pharm. 2014;11:2040–50.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sugimoto K, Hayakawa F, Shimada S, Morishita T, Shimada K, Katakai T, et al. Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Sci Rep. 2015;5:13054.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Paez-Ribes M, Man S, Xu P, Kerbel RS. Development of patient derived xenograft models of overt spontaneous breast cancer metastasis: a cautionary note. PLoS One. 2016;11:e0158034.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhao H, Nolley R, Chan AMW, Rankin EB, Peehl DM. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation. Cancer Biol Ther. 2017;18:863–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Eyre R, Alférez DG, Spence K, Kamal M, Shaw FL, Simões BM, et al. Patient-derived mammosphere and xenograft tumour initiation correlates with progression to metastasis. J Mammary Gland Biol Neoplasia. 2016;21:99–109.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Brown KM, Xue A, Mittal A, Samra JS, Smith R, Hugh TJ. Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review. Oncotarget. 2016;7:66212–25.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer. 2015;15:311–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Kim KM, Shim JK, Chang JH, Lee JH, Kim SH, Choi J, et al. Failure of a patient-derived xenograft for brain tumor model prepared by implantation of tissue fragments. Cancer Cell Int. 2016;16:43.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Harris AL, Joseph RW, Copland JA. Patient-derived tumor xenograft models for melanoma drug discovery. Expert Opin Drug Discov. 2016;11:895–906.CrossRefPubMedGoogle Scholar
  20. 20.
    Rao RR, Peterson AW, Ceccarelli J, Putnam AJ, Stegemann JP. Matrix composition regulates three-dimensional network formation by endothelial cells and mesenchymal stem cells in collagen/fibrin materials. Angiogenesis. 2012;15:253–64.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Koolwijk P, van Erck MG, de Vree WJ, Vermeer MA, Weich HA, Hanemaaijer R, et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol. 1996;132:1177–88.CrossRefPubMedGoogle Scholar
  22. 22.
    Nakatsu MN, Sainson RC, Aoto JN, Taylor KL, Aitkenhead M, Pérez-del-Pulgar S, et al. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc Res. 2003;66:102–12.CrossRefPubMedGoogle Scholar
  23. 23.
    Riis P. Perspectives on the fifth revision of the Declaration of Helsinki. JAMA. 2000;284:3045–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. Cell profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7:R100.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Young JL, Holle AW, Spatz JP. Nanoscale and mechanical properties of the physiological cell-ECM microenvironment. Exp Cell Res. 2016;343:3–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Pham K, Delitto D, Knowlton AE, Hartlage ER, Madhavan R, Gonzalo DH, et al. Isolation of pancreatic cancer cells from a patient-derived xenograft model allows for practical expansion and preserved heterogeneity in culture. Am J Pathol. 2016;186:1537–46.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P. Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol. 2017;10:106.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kawaguchi T, Foster BA, Young J, Takabe K. Current update of patient-derived xenograft model for translational breast cancer research. J Mammary Gland Biol Neoplasia. 2017;22:131–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Lee HW, Lee K, Kim DG, Yang H, Nam DH. Facilitating tailored therapeutic strategies for glioblastoma through an orthotopic patient-derived xenograft platform. Histol Histopathol. 2016;31:269–83.PubMedGoogle Scholar
  30. 30.
    Chokshi C, Dhillon M, McFarlane N, Venugopal C, Singh SK. Development of a patient-derived xenograft model using brain tumor stem cell systems to study cancer. Methods Mol Biol. 2016;1458:231–45.CrossRefPubMedGoogle Scholar
  31. 31.
    Fritsch M, Schmidt N, Gröticke I, Frisk AL, Keator CS, Koch M, et al. Application of a patient derived xenograft model for predicative study of uterine fibroid disease. PLoS One. 2015;10:e0142429.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Takakura K, Shibazaki Y, Yoneyama H, Fujii M, Hashiguchi T, Ito Z, et al. Inhibition of cell proliferation and growth of pancreatic cancer by silencing of carbohydrate sulfotransferase 15 in vitro and in a xenograft model. PLoS One. 2015;10:e0142981.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, et al. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biol Ther. 2015;16:438–49.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Andrade SS, Sumikawa JT, Castro ED, Batista FP, Paredes-Gamero E, Oliveira LC, et al. Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis—influence of platelets and fibrin bundles on the behavior of breast tumor cells. Oncotarget. 2017;8:16851–74.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583–92.CrossRefPubMedGoogle Scholar
  37. 37.
    Hong S, Jung BY, Hwang C. Multilayered engineered tissue sheets for vascularized tissue regeneration. Tissue Eng Regen Med. 2017;14:371–81.CrossRefGoogle Scholar
  38. 38.
    Steinkamp MP, Winner KK, Davies S, Muller C, Zhang Y, Hoffman RM, et al. Ovarian tumor attachment, invasion, and vascularization reflect unique microenvironments in the peritoneum: insights from xenograft and mathematical models. Front Oncol. 2013;3:97.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Zamora DO, Natesan S, Becerra S, Wrice N, Chung E, Suggs LJ, et al. Enhanced wound vascularization using a dsASCs seeded FPEG scaffold. Angiogenesis. 2013;16:745–57.CrossRefPubMedGoogle Scholar
  40. 40.
    Zheng Y, Roberts MA. Tissue engineering: scalable vascularized implants. Nat Mater. 2016;15:597–9.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Zhang Q, Johnson JA, Dunne LW, Chen Y, Iyyanki T, Wu Y, et al. Decellularized skin/adipose tissue flap matrix for engineering vascularized composite soft tissue flaps. Acta Biomater. 2016;35:166–84.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2:247–50.CrossRefPubMedGoogle Scholar
  43. 43.
    Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508–23.CrossRefPubMedGoogle Scholar
  44. 44.
    Izumchenko E, Meir J, Bedi A, Wysocki PT, Hoque MO, Sidransky D. Patient-derived xenografts as tools in pharmaceutical development. Clin Pharmacol Ther. 2016;99:612–21.CrossRefPubMedGoogle Scholar
  45. 45.
    Varešlija D, Cocchiglia S, Byrne C, Young L. Patient-derived xenografts of breast cancer. Methods Mol Biol. 2017;1501:327–36.CrossRefPubMedGoogle Scholar

Copyright information

© The Korean Tissue Engineering and Regenerative Medicine Society and Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Biomedical Engineering Research Center, Asan Institute for Life SciencesAsan Medical CenterSeoulSouth Korea
  2. 2.University of Ulsan College of MedicineSeoulSouth Korea
  3. 3.Division of Hepato-Biliary and Pancreatic Surgery, Department of SurgeryUniversity of Ulsan College of Medicine and Asan Medical CenterSeoulSouth Korea

Personalised recommendations